Ascorbic acid/menadione

Drug Profile

Ascorbic acid/menadione

Alternative Names: Apatone; Apatone-B

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Summa Health System
  • Developer IC-MedTech; Summa Health System
  • Class Antineoplastics; Naphthoquinones; Small molecules; Vitamins
  • Mechanism of Action Antioxidants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bladder cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Joint disorders
  • Phase I/II Prostate cancer
  • No development reported Polycystic kidney disease
  • Discontinued Wounds

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Polycystic-kidney-disease in USA (PO)
  • 28 Jan 2016 Ascorbic acid/menadione is available for licensing -http://www.ic-medtech.com/partnerships_licensing.html
  • 10 Aug 2015 Development of ascorbic acid/menadione is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top